On Monday, Neumora Therapeutics Inc. (NASDAQ: NMRA) opened lower -14.80% from the last session, before settling in for the closing price of $16.49. Price fluctuations for NMRA have ranged from $8.33 to $21.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 59.37% at the time writing. With a float of $54.91 million, this company’s outstanding shares have now reached $158.83 million.
In an organization with 124 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc. (NMRA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Neumora Therapeutics Inc. is 65.69%, while institutional ownership is 27.62%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc. (NMRA) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -1.14 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.36) by -0.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.37% per share during the next fiscal year.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Trading Performance Indicators
Check out the current performance indicators for Neumora Therapeutics Inc. (NMRA). In the past quarter, the stock posted a quick ratio of 17.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc. (NMRA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.86 million. That was better than the volume of 0.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.42%. Additionally, its Average True Range was 1.03.
During the past 100 days, Neumora Therapeutics Inc.’s (NMRA) raw stochastic average was set at 64.58%, which indicates a significant increase from 28.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.03% in the past 14 days, which was higher than the 60.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.78, while its 200-day Moving Average is $12.81. However, in the short run, Neumora Therapeutics Inc.’s stock first resistance to watch stands at $15.52. Second resistance stands at $16.99. The third major resistance level sits at $17.84. If the price goes on to break the first support level at $13.20, it is likely to go to the next support level at $12.34. The third support level lies at $10.87 if the price breaches the second support level.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Key Stats
There are currently 159,524K shares outstanding in the company with a market cap of 2.25 billion. Presently, the company’s annual sales total 0 K according to its annual income of -235,930 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -58,700 K.
